Ebola virus vaccine - Novavax

Drug Profile

Ebola virus vaccine - Novavax

Alternative Names: Ebola virus recombinant glycoprotein nanoparticle vaccine; EBOV-GP Vaccine; Recombinant Ebola glycoprotein vaccine; Recombinant Ebola GP vaccine

Latest Information Update: 04 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novavax
  • Class Glycoproteins; Recombinant proteins; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 23 Jul 2015 Final immunogenicity data from a phase I trial in Ebola virus infections released by Novavax
  • 27 Mar 2015 Pharmacodynamics and adverse events data from a preclinical study in Ebola virus infections (Prevention) released by Novavax
  • 12 Feb 2015 Phase-I clinical trials in Ebola virus infections (Prevention) in Australia (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top